Non-interventional Study on the Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (MILOS)
Latest Information Update: 24 Nov 2024
Price :
$35 *
At a glance
- Drugs Bempedoic acid (Primary) ; Bempedoic acid/ezetimibe (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms MILOS
- Sponsors Daiichi Sankyo Europe
- 30 Sep 2024 According to Daiichi Sankyo (hereafter, Daiichi Sankyo) media release, final 2-year follow-up data from the German cohort of the multinational, European observational MILOS study, presented in Hamburg, Germany at DGK Hertztage 2024.
- 27 Sep 2024 Results comprising 973 patients from 125 sites in Germany published in a Daiichi Sankyo media release.
- 28 Aug 2023 Results (n=992) assessing evaluate the effectiveness and safety of BA and its FDC in routine clinical practice in Germany presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology